CPIC 2026丨The Era of Superintelligent Agents for Chinese Innovative Drugs-TONACEA

CPIC 2026丨The Era of Superintelligent Agents for Chinese Innovative Drugs

Update time:

2026-07-12 08:54

Reads:

When AI Evolves from a Supporting Tool to the Core of R&D, the Underlying Logic of Drug Discovery Is Being Completely Reconstructed. From de novo design of proteins and antibodies to intelligent R&D paradigms for biologics, from deep industry-academia-research collaboration to the value realization of AI-native biologics — the era of superintelligence has arrived.

The full agenda for the "Superintelligence Era of Chinese Innovative Drugs" session has been updated today. The session brings together industry giants and AI drug discovery pioneers — including Sino Biopharmaceutical, MEGAROBO, Zijing Xingyu, and Tushenzhihé — as well as core decision-makers from innovative pharma companies such as Jiyu Biopharma, Fosun Pharma, and Innocare. Deep discussions will focus on key topics including AI-driven macromolecular drug R&D, de novo design of proteins and antibodies, and the scientific breakthroughs and commercial translation of AI-native biologics — presenting a feast of ideas from technology frontiers to industrial implementation.

July 22–24, National Exhibition and Convention Center (Shanghai). We look forward to exploring the new paradigm of drug R&D in the superintelligence era with you.

Session Agenda

Co-Organizer: Toursynbio

Conference Time: July 23, 10:00-12:30

Planner
Yuguang Wang: Founder & CEO, Toursun Synbio

10:00-10:05　Opening Remarks

10:05-10:25　How Capital Reshapes the AI Pharma Ecosystem

Zhuoran Guo: Senior Vice President, CITIC Securities

10:25-10:45　Ecological Reconstruction, Intelligent Leap: The Innovative Narrative of Chinese Biopharmaceuticals
Xin Xie: Executive Director & Senior Vice President, Sino Biopharmaceutical Limited; Senior Vice President, CP Pharmaceutical Group

10:45-11:00　Break

11:00-11:20　Macromolecular Drug Discovery and Development in the Era of AI Agents
Weining Lin: Chief AI Scientist, Toursun Synbio

11:20-11:40　De Novo Design of Miniproteins and Antibodies via Generative AI
Vice President, Toursun Synbio

11:40-11:50　Signing Ceremony

Signing Guests:
Xin Xie: Executive Director & Senior Vice President, Sino Biopharmaceutical Limited; Senior Vice President, CP Pharmaceutical Group
Yan Zhang: Co-founder & Vice President, MegaRobo Technologies
Jian Jun Wu: Founder & CEO, Asmote
Yuguang Wang: Founder & CEO, Toursun Synbio

11:50-12:30　Panel: AI-Native Biologics R&D: How Can Scientific Superintelligence Break the Boundaries of Drug Discovery?
Bingshi Guo (Moderator): General Manager, Macromolecular Drug Division, JeYou Pharmaceutical Technology
Jingjun Qiu: Global Partner, Fosun Pharma
COO, InnoCare Pharma
Dan Liu: Partner, Pivotal Bioventure Capital
Yan Zhang: CEO, Everest Medicines Limited
Yuguang Wang: Founder & CEO, Toursun Synbio

CPIC 2026 l 800+ Speakers from 22 Countries! Who are the overseas guests?

AI Drug Discovery, New Tracks Emerge